- Home
- CNTA vs AZTA Comparison
CNTA vs AZTA Comparison
Compare CNTA & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTA
- AZTA
- Stock Information
- Founded
- CNTA 2020
- AZTA 1978
- Country
- CNTA United Kingdom
- AZTA United States
- Employees
- CNTA N/A
- AZTA N/A
- Industry
- CNTA Biotechnology: Pharmaceutical Preparations
- AZTA Industrial Machinery/Components
- Sector
- CNTA Health Care
- AZTA Technology
- Exchange
- CNTA Nasdaq
- AZTA Nasdaq
- Market Cap
- CNTA 1.8B
- AZTA 1.8B
- IPO Year
- CNTA 2021
- AZTA 1995
- Fundamental
- Price
- CNTA $12.30
- AZTA $26.77
- Analyst Decision
- CNTA Strong Buy
- AZTA Buy
- Analyst Count
- CNTA 10
- AZTA 3
- Target Price
- CNTA $26.11
- AZTA $50.67
- AVG Volume (30 Days)
- CNTA 617.5K
- AZTA 945.6K
- Earning Date
- CNTA 05-20-2025
- AZTA 05-07-2025
- Dividend Yield
- CNTA N/A
- AZTA N/A
- EPS Growth
- CNTA N/A
- AZTA N/A
- EPS
- CNTA N/A
- AZTA N/A
- Revenue
- CNTA N/A
- AZTA $669,171,000.00
- Revenue This Year
- CNTA N/A
- AZTA N/A
- Revenue Next Year
- CNTA N/A
- AZTA $5.38
- P/E Ratio
- CNTA N/A
- AZTA N/A
- Revenue Growth
- CNTA N/A
- AZTA 4.70
- 52 Week Low
- CNTA $7.75
- AZTA $24.06
- 52 Week High
- CNTA $19.09
- AZTA $63.58
- Technical
- Relative Strength Index (RSI)
- CNTA 40.97
- AZTA 43.19
- Support Level
- CNTA $11.88
- AZTA $23.91
- Resistance Level
- CNTA $14.39
- AZTA $27.06
- Average True Range (ATR)
- CNTA 0.79
- AZTA 1.41
- MACD
- CNTA -0.00
- AZTA 0.57
- Stochastic Oscillator
- CNTA 18.68
- AZTA 67.14
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
About AZTA Azenta Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.